OPKO Health acquires ModeX Therapeutics for $300M in stock; appoints Dr. Zerhouni as President

OPKO HEALTH, INC.

Merger consideration of $300M paid via 89,907,310 shares of OPKO common stock.
Dr. Elias Zerhouni appointed President and Vice Chairman; Dr. Gary Nabel named Chief Innovation Officer and director.
Alexis Borisy appointed to board; receives 312,612 restricted shares and options.
Frost Gamma Investments Trust and holders of ~88% of consideration shares subject to 4-year lockup.
Zerhouni employment: $900K base, target bonus ≥50%; Nabel: $750K base, target bonus ≥50%.

item 1.01 item 3.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Alexis Borisy

director

OPK · OPKO HEALTH, INC.

Filed: May 13, 2022, 7:59 PM ET

On the Closing Date, in connection with the transactions contemplated by the Merger Agreement, the Board expanded its size from 10 to 13 directors and appointed Elias Zerhouni, M.D. as the Company’s President and Vice Chairman of the Board, Gary Nabel, M.D., Ph.D., as the Company’s Chief Innovation Officer and a director, and Alexis Borisy as a director.

Appointed

Gary Nabel

Chief Innovation Officer and a director

OPK · OPKO HEALTH, INC.

Filed: May 13, 2022, 7:59 PM ET

On the Closing Date, in connection with the transactions contemplated by the Merger Agreement, the Board expanded its size from 10 to 13 directors and appointed Elias Zerhouni, M.D. as the Company’s President and Vice Chairman of the Board, Gary Nabel, M.D., Ph.D., as the Company’s Chief Innovation Officer and a director, and Alexis Borisy as a director.

Appointed

Elias Zerhouni

President and Vice Chairman of the Board

OPK · OPKO HEALTH, INC.

Filed: May 13, 2022, 7:59 PM ET

On the Closing Date, in connection with the transactions contemplated by the Merger Agreement, the Board expanded its size from 10 to 13 directors and appointed Elias Zerhouni, M.D. as the Company’s President and Vice Chairman of the Board, Gary Nabel, M.D., Ph.D., as the Company’s Chief Innovation Officer and a director, and Alexis Borisy as a director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Alexis Borisy was appointed as director at OPKO HEALTH, INC..

Action: appointed
Role: director

Exact text from the filing

On the Closing Date, in connection with the transactions contemplated by the Merger Agreement, the Board expanded its size from 10 to 13 directors and appointed Elias Zerhouni, M.D. as the Company’s President and Vice Chairman of the Board, Gary Nabel, M.D., Ph.D., as the Company’s Chief Innovation Officer and a director, and Alexis Borisy as a director.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Gary Nabel was appointed as Chief Innovation Officer and a director at OPKO HEALTH, INC..

Action: appointed
Role: Chief Innovation Officer and a director

Exact text from the filing

On the Closing Date, in connection with the transactions contemplated by the Merger Agreement, the Board expanded its size from 10 to 13 directors and appointed Elias Zerhouni, M.D. as the Company’s President and Vice Chairman of the Board, Gary Nabel, M.D., Ph.D., as the Company’s Chief Innovation Officer and a director, and Alexis Borisy as a director.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Elias Zerhouni was appointed as President and Vice Chairman of the Board at OPKO HEALTH, INC..

Action: appointed
Role: President and Vice Chairman of the Board

Exact text from the filing

On the Closing Date, in connection with the transactions contemplated by the Merger Agreement, the Board expanded its size from 10 to 13 directors and appointed Elias Zerhouni, M.D. as the Company’s President and Vice Chairman of the Board, Gary Nabel, M.D., Ph.D., as the Company’s Chief Innovation Officer and a director, and Alexis Borisy as a director.

View on SEC.gov

OPKO HEALTH, INC. filing history →

Source: SEC EDGAR

accession 0000944809-22-000029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.